Lung Cancer Twitter Coverage and Key Studies at ASCO 2015
•
1 like•461 views
This document provides an overview and analysis of Twitter coverage of the 2015 American Society of Clinical Oncology (ASCO) annual meeting. It includes statistics on the total number of tweets during the meeting and breakdowns of the tweets by day and topic. The top tumor types discussed were lung cancer, breast cancer, and melanoma. Key clinical studies for each of these cancers are also highlighted and the sentiment of healthcare professionals around these studies is analyzed. Influential healthcare professionals on Twitter for each topic are also identified.
Recommended
Recommended
More Related Content
Similar to Lung Cancer Twitter Coverage and Key Studies at ASCO 2015
Similar to Lung Cancer Twitter Coverage and Key Studies at ASCO 2015 (20)
Lung Cancer Twitter Coverage and Key Studies at ASCO 2015
- 1. − 1 − © 2015 ZS Associates | CONFIDENTIAL ASCO 2015 Overview Infographic_V2 3991,356 947 #ASCO15 TWITTER COVERAGE 6,877 14,591 15,163 May 29-June 2, 2015 13,668 6,572 ASCO 2015 TOTAL TWEETS 56,871 FRI SAT SUN MON TUE ASCO 2015 TOP TUMOR TYPES WORLD WIDE REACH 2014 2015 14Mn 44Mn Lung Cancer Breast Cancer Melanoma Lymphoma Multiple Myeloma 1.6X MORE HCPs POSTED ABOUT ASCO 2015 AS COMPARED TO LAST YEAR 878 458 423 1.3K 2.1K 2014 2015 317 408 TOP 5 INFLUENTIAL HCPs (Driving Trending Conversations) @mtmdphd (Mike Thompson) @subatomicdoc (Matthew Katz) @fischmd (Michael Fisch) @drattai (Deanna Attai) @drdonsdizon RTs COVERAGE BY HCPs 126 119 71 51 70 TOP POSTS BY HCPs (Health Care Professionals) (Driving the maximum number of Retweets) KEY STAKEHOLDERS 28% OF THE TWEETS ABOUT ASCO 2015 WERE BY HCPs On avg. each HCP posted 8 tweets around ASCO 2015 2X more than other stakeholders Impact where it matters Follow us on Twitter @ZSAssociates 5,762 3,523 1,961 1,790 1,627 INCREASE IN TOTAL TWEETS OVER LAST YEAR2X NO. OF TWEETS AROUND KEY ASCO THEMES Immunotherapy Cost Value Price 2,673 (Don S Dizon)
- 2. − 1 − © 2015 ZS Associates | CONFIDENTIAL Lung Cancer Infographic New LUNG CANCER ASCO 2015 LUNG CANCER TWITTER VOLUME TRENDS T W I T T E R C O V E R A G E LUNG CANCER AUTHOR CATEGORIZATION KEY CLINICAL STUDIES ON LUNG CANCER 647 280 164 65 CheckMate 057 CheckMate 017 AURA Study KEYNOTE-028 HCP SENTIMENT AROUND KEY STUDIES ON LUNG CANCER Follow us on Twitter @ZSAssociates Impact where it matters. STEVEN EISENBERG 1.3K @n8pennell 49 JACK WEST 7.6K @jackwestmd 60 MATTHEW KATZ 10.6K @subatomicdoc 63 NAOTO UENO 8.6K @teamoncology 46 MIKE THOMPSON 8.5K @mtmdphd 53 ROBERT WEST 16.6K @westr 53NA 67% of HCPs … HCPs were concerned that a low percentage of patients were eligible for the PD-L1+ based trial 621 1,532 2,013 1,159 437 MAY 29 MAY 30 MAY 31 JUNE 1 JUNE 2 ASCO 2015 1,510 5,762 4xIncrease in number of tweets about lung cancer HCPs Companies Support Groups Patients Others** Media 21% 7% 2% 5% 4% 48% Commu- nicators* 11% 2% Institutions *Authors who tweeted frequently about health care topics **Authors who cannot be classified into any major stakeholder group Ph III Non-squamous: Nivolumab vs. Docetaxel Ph I EGFR-T790M mutation: AZD9291 Ph III Squamous: Nivolumab vs. Docetaxel Ph Ib SCLC: Pembrolizumab KEYNOTE- 028 Overall Response rate of 35% was considered promising by HCPs BIOMARKERS 174 NSCLC 1,135 (By number of tweets) SCLC TYPES OF LUNG CANCER (By number of tweets) CheckMate 057 CheckMate 017 AURA Study KEYNOTE 028 A neutral score indicates that the study was mentioned without any sentiment 25% 67% 8% Twitter Followers Klout Score TOP INFLUENTIAL HCPs FOR LUNG CANCER 12% 62% 27% Numberoftweets 19% 76% 5% 31% 64% 5% Mixed reaction in HCPs about the study due to improved outcomes in PD-L1+ patients only ... tweeting about the CheckMate 057 trial were impressed by the Overall Survival HCPs were excited about adopting Nivo as the 2L non-squam standard of care ASCO 2014 (By number of tweets) Squamous 297 515 154PD-L1 EGFR ALK T790M 84 232 313 Non- Squamous
- 3. − 1 − © 2015 ZS Associates | CONFIDENTIAL Lung Cancer Infographic New 34% 66% BREAST CANCER ASCO 2015 T W I T T E R C O V E R A G E 293 880 648 1,270 432 MAY 29 MAY 30 MAY 31 JUNE 1 JUNE 2 HCPs Companies Support Groups Patients Others** Media 21% 8% 3% 6% 4% 44% 343 193 83 75 PALOMA-3 NSABP B-35 ExteNET MARIANNE NSABP B-35 ExteNET 31% 69% 14% 14% 72% 54% 14% 32% PALOMA-3 66% of HCPs .. … tweeting about the PALOMA-3 study appreciated the improved PFS Anastrozole's better Breast Cancer free survival rate and fewer side effects than Tamoxifen were discussed widely 8.8K 8.7K12.3K 10.8K13K 9.3K DEANNA ATTAI @drattai NAOTO UENO @teamoncology MIKE THOMPSON @mtmdphd Follow us on Twitter @ZSAssociates Impact where it matters. KEY ASCO BREAST CANCER THEMES 179 Surgical Approaches TNBC 215 66165 (By number of tweets) ASCO 2014 ASCO 2015 2,023 3,523 73 % Increase in number of tweets about Breast Cancer MARIANNE JOHN CROWN @ProfJohnCrown MICHAEL FISCH @fischmd MATTHEW KATZ @subatomicdoc 56 59 67 63 50 65 NSABP B-35 TOXICITY DFS Neratinib was seen to offer minimal benefit when weighed against its toxicity ExteNET study Commu- nicators* 12% 2% Institutions Numberoftweets A neutral score indicates that the study was mentioned without any sentiment *Authors who tweeted frequently about health care topics **Authors who cannot be classified into any major stakeholder group The MDV3100-11 (enzalutamide) trial received minimal coverage, with only 17 tweets Genetic Testing Survivorship Twitter Followers Klout Score Ph III: (palbociclib + fulvestrant) vs. (placebo + fulvestrant) Ph III: (RT* + anastrozole) vs. (RT* + tamoxifen) Ph III: neratinib vs. placebo (T-DM1 + placebo) vs. (T-DM1 + pertuzumab) vs. (trastuzumab + taxane) Ph III BREAST CANCER TWITTER VOLUME TRENDS BREAST CANCER AUTHOR CATEGORIZATION KEY CLINICAL STUDIES ON BREAST CANCER (By number of tweets) HCP SENTIMENT AROUND KEY STUDIES ON BREAST CANCER TOP INFLUENTIAL HCPs FOR BREAST CANCER *Radiation Therapy
- 4. − 1 − © 2015 ZS Associates | CONFIDENTIAL Melanoma Infographic Re MELANOMA ASCO 2015 MELANOMA TWITTER VOLUME TRENDS T W I T T E R C O V E R A G E MELANOMA AUTHOR CATEGORIZATION KEY CLINICAL STUDIES ON MELANOMA 799 CheckMate 067/069 nivolumab + Ipilimumab 48 KEYNOTE 001 pembrolizumab HCP SENTIMENT AROUND KEY STUDIES ON MELANOMA Impact where it matters. 50% of HCPs .. … who tweeted about Melanoma mentioned the Nivolumub + Ipilimumab study KEY ASCO MELANOMA THEMES 204 60 Survival Cost Follow us on Twitter @ZSAssociates TOP INFLUENTIAL HCPs FOR MELANOMA HCPs Companies Support Groups Patients Others** Media 25% 7% 2% 6% 5% 44% Commun icators* 10% 1% Institutions MAY 30 MAY 31 JUNE 1 JUNE 2MAY 29 81 414 847 338 281 Numberoftweets KEYNOTE 001 74% 36% 27% 73% A neutral score indicates that the study was mentioned without any sentiment ASCO 2014 ASCO 2015 542 1,961 3.6xIncrease in number of tweets about Melanoma …around the Nivolumab + Ipilmumab, driven most frequently by HCPs appreciating the increased PFS PFS increased to 73% positive sentiment.. …for Pembrolizumab, was mostly due to favorable reactions to the durability of response in metastatic patients KEYNOTE-001 36% positive sentiment.. *Authors who tweeted frequently about health care topics **Authors who cannot be classified into any major stakeholder group 21 PD-L1 Testing (By number of tweets) (By number of tweets) (By number of tweets) Twitter Followers Klout Score MIKE THOMPSON 8.7K @mtmdphd Prof. JOHN CROWN 13.1K @ProfJohnCrown ERIN D WHITMAN 2.5K @melanoma_doctor OLIVIER BRANFORD 19.4K @olivierbranford MICHEAL FISCH 12.4K @fischmd CheckMate 067/069 CheckMate 067/069 NA655956NA